Japan approves Amicus Therapeutics' treatment for late-onset Pompe disease

Amicus Therapeutics (NASDAQ:FOLD) secured Japanese approval for Pombiliti + Opfolda for late-onset Pompe disease, significantly expanding the two-component therapy's global market presence. This key regulatory win coincides with the company's mixed Q1 2025 results, where adjusted EPS of $0.03 surpassed expectations, but revenue of $125.25 million fell short of forecasts. Consequently, Amicus slightly lowered its full-year 2025 total revenue growth guidance to 15-22% from 17-24%, despite Pombiliti + Opfolda sales jumping 92% year-over-year, while reiterating its H2 2025 GAAP profitability target.

Analysis

Amicus Therapeutics (NASDAQ:FOLD) has secured a significant regulatory victory with the approval of its Pombiliti + Opfolda therapy for late-onset Pompe disease in Japan, completing its market access in all major global regions. This positive development, however, is juxtaposed with mixed first-quarter 2025 financial results. While the company posted an unexpected adjusted earnings per share of $0.03, beating consensus estimates of -$0.02, it missed on revenue, reporting $125.25 million against a forecast of $136.65 million. Despite the miss, total revenue grew 15% year-over-year, driven by a notable 92% jump in Pombiliti + Opfolda sales to $21.0 million, while its established drug, Galafold, saw more modest 6% growth. In a move signaling caution, Amicus has revised its full-year 2025 revenue growth guidance downwards to 15-22% from a previous range of 17-24%, citing lowered expectations for Pombiliti + Opfolda. The company is maintaining its goal of achieving GAAP profitability in the second half of 2025, supported by a strong 90.6% gross margin and a cash position of $250.6 million. Strategic pipeline expansion is also underway with the licensing of U.S. rights for a Phase 3 kidney disease treatment.

Key Decisions for Investors

• Investors should weigh the positive long-term catalyst of the Japanese approval for Pombiliti + Opfolda against the near-term concern raised by the downward revision of the therapy's sales expectations and overall 2025 revenue guidance.
• The company's reiterated commitment to achieving GAAP profitability in the second half of 2025 is a critical milestone to monitor, as its achievement would validate management's operational control despite revenue headwinds.
• Closely track the quarterly sales ramp-up of Pombiliti + Opfolda, as its performance is the primary driver for future growth and essential for justifying the company's valuation, especially given the maturing growth profile of Galafold.
• Consider the in-licensing of DMX-200 as a strategic move to diversify risk, but recognize that the company's financial trajectory remains overwhelmingly dependent on the commercial execution of its two approved therapies.